Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial.

ABSTRACT:

Aims

The efficacy and safety of the non-steroidal mineralocorticoid receptor antagonist, finerenone, have not been examined in patients without diabetes. We examined the efficacy and safety of finerenone, compared with placebo, according to glycaemic status in FINEARTS-HF.

Methods and results

A total of 6001 patients with heart failure (HF) with New York Heart Association functional class II-IV, left ventricular ejection fraction ≥40%, evidence of structural heart disease, and elevated N-terminal pro-B-type natriuretic peptide levels were randomized to finerenone or placebo. The effect of finerenone according to glycaemic status (i.e. normoglycaemia [no investigator-reported history of diabetes and glycated haemoglobin (HbA1c) <5.7%], pre-diabetes [no investigator-reported h

SUBMITTER: Butt JH 

PROVIDER: S-EPMC12370580 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature